Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma. uri icon

Overview

abstract

  • Tumor burden is a key consideration for the treatment of solid malignancies. Large baseline tumor size (an assessment of volume of disease in target lesions prior to treatment), elevated lactate dehydrogenase (LDH), and site of disease are prognostic of poor overall survival (OS) for patients with advanced melanoma treated with pembrolizumab. Clin Cancer Res; 24(20); 4915-7. ©2018 AACR See related article by Joseph et al., p. 4960.

publication date

  • June 14, 2018

Research

keywords

  • Melanoma
  • Skin Neoplasms

Identity

Scopus Document Identifier

  • 85054995411

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-18-1311

PubMed ID

  • 29903895

Additional Document Info

volume

  • 24

issue

  • 20